Nucleophosmin leukaemic mutants contain C-terminus peptides that bind HLA class I molecules [1]

Leukemia

Volumn 22, Issue 2, 2008, Pages 424-426

  Liso, A ^a   Colau, D ^b   Benmaamar, R ^b   De Groot, A ^c   Martin, W ^c   Benedetti, R ^d   Specchia, G ^e   Martelli, M P ^e   Coulie, P ^b   Falini, B ^d  

^a UNIVERSITY OF FOGGIA   (Italy)

^b DE DUVE INSTITUTE   (Belgium)

^c EpiVax Inc   (United States)

^d UNIVERSITY OF PERUGIA   (Italy)

^e UNIVERSITY OF BARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HLA A ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA B ANTIGEN; HLA DR ANTIGEN; MUTANT PROTEIN; NUCLEOPHOSMIN;

ACUTE GRANULOCYTIC LEUKEMIA; ALLELE; AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CELLULAR IMMUNITY; COMPUTER MODEL; CONTROLLED STUDY; HUMAN; IN VITRO STUDY; LETTER; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SCORING SYSTEM; SEQUENCE ANALYSIS; T LYMPHOCYTE; TUMOR IMMUNOLOGY; WILD TYPE;

EID: 39149085355     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404887     Document Type: Letter

References (11)

1. Tallman MS. New agents for the treatment of acute myeloid leukemia. Best Pract Res Clin Haematol 2006; 19: 311-320.
2. Klammer MandRoddie PH. Current progress in the development of a cell-based vaccine for the immunotherapy of acute myeloid leukemia. Expert Rev Vaccines 2006; 5: 211-222.
3. Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005; 352: 254-266.
4. Falini B, Nicoletti I, Martelli MF, Mecucci C. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+AML): Biologic and clinical features. Blood 2007; 109: 874-885.
5. Falini B, Bolli N, Shan J, Martelli MP, Liso A, Pucciarini A et al Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+AML. Blood 2006; 107: 4514-4523.
6. De Groot AS, Rayher J, Martin W. Modelling the immunogenicity of therapeutic proteins using T cell epitope mapping. Dev Biol (Basel) 2003; 112: 71-80.
7. De Groot AS, Jesdale B, Martin W, Saint Aubin C, Sbai H, Bosma A et al. Mapping cross-clade HIV-1 vaccine epitopes using a bioinformatics approach. Vaccine 2003; 21: 4486-4504.
8. Altman JD, Moss PA, Goulder PJ, Barouch DH, McHeyzer-Williams MG, Bell JI et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996; 274: 94-96.
9. Callan MF, Tan L, Annels N, Ogg GS, Wilson JD, O'Callaghan CA et al Direct visualization of antigen-specific CD8+T cells during the primary immune response to Epstein-Barr virus In vivo. J Exp Med 1998; 187: 1395-1402.
10. Brodsky FM, Parham P. Monomorphic anti-HLA-A,B,C monoclonal antibodies detecting molecular subunits and combinatorial determinants. J Immunol 1982; 128: 129-135.
11. Wesierska-Gadek J, Penner E, Hitchman E, Kier P, Sauermann G. Nucleolar proteins B23 and C23 as target antigens in chronic graft-versus-host disease. Blood 1992; 79: 1081-1086.